[go: up one dir, main page]

WO2000040576A2 - Compose cyclique - Google Patents

Compose cyclique Download PDF

Info

Publication number
WO2000040576A2
WO2000040576A2 PCT/JP2000/000018 JP0000018W WO0040576A2 WO 2000040576 A2 WO2000040576 A2 WO 2000040576A2 JP 0000018 W JP0000018 W JP 0000018W WO 0040576 A2 WO0040576 A2 WO 0040576A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
compound
amino
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2000/000018
Other languages
English (en)
Other versions
WO2000040576A3 (fr
Inventor
Kiyoshi Taniguchi
Masahiro Neya
Takeshi Terasawa
Hitoshi Yamazaki
Kentaro Sato
Kumi Hosoi
Yasuyo Tomishima
Noriko Yoshida
Yoshimasa Imamura
Hisashi Takasugi
Hiroyuki Setoi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP8068A external-priority patent/AUPP806899A0/en
Priority claimed from AUPQ1702A external-priority patent/AUPQ170299A0/en
Priority to AU18905/00A priority Critical patent/AU759900B2/en
Priority to HK02106999.6A priority patent/HK1045312A1/zh
Priority to KR1020017008512A priority patent/KR20010102968A/ko
Priority to DE60009260T priority patent/DE60009260T2/de
Priority to CA002357874A priority patent/CA2357874A1/fr
Priority to JP2000592284A priority patent/JP2002534424A/ja
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to EP00900122A priority patent/EP1140895B1/fr
Priority to AT00900122T priority patent/ATE262517T1/de
Priority to MXPA01006896A priority patent/MXPA01006896A/es
Priority to BR0008589-8A priority patent/BR0008589A/pt
Publication of WO2000040576A2 publication Critical patent/WO2000040576A2/fr
Publication of WO2000040576A3 publication Critical patent/WO2000040576A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
    • C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to new compounds and pharmaceutically acceptable salts thereof.
  • MMP matrix metalloproteinases
  • TNF ⁇ tumor necrosis factor ⁇
  • One object of the present invention is to provide new and useful cyclic compounds and pharmaceutically acceptable salts thereof, and to provide a process for preparing said new cyclic compound and salts thereof, which have pharmacological activities such as MMP- or TNF ⁇ - inhibitory activity and the like.
  • Another object of the present invention is to provide a pharmaceutical composition
  • a pharmaceutical composition comprising, as an active ingredient, said cyclic compound or a pharmaceutically acceptable salt thereof.
  • a further object of the present invention is to provide use of said cyclic compounds and pharmaceutically acceptable salts thereof as medicaments for prophylactic and therapeutic treatment of MMP- or TNF ⁇ -mediated diseases.
  • a still further object of the present invention is to provide a method for using the same for the treatment and/or the prevention of MMP- or TNF ⁇ -mediated diseases in mammals, especially humans.
  • the compounds of the present invention have inhibitory activity on MMP or the production of TNF ⁇ , and are useful for the treatment and/or prevention of diseases such as stroke, arthritis, cancer, tissue ulceration, decubitus ulcer, restenosis, periodontal disease, epidermolysis bullosa, scleritis, psoriasis and other diseases characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases caused by the production of TNF ⁇ .
  • diseases such as stroke, arthritis, cancer, tissue ulceration, decubitus ulcer, restenosis, periodontal disease, epidermolysis bullosa, scleritis, psoriasis and other diseases characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases caused by the production of TNF ⁇ .
  • Matrix-degrading metalloproteases such as gelatinase (MMP-2, MMP-9) , stromelysin (MMP-3) and collagenase (MMP-1, MMP-8, MMP-13) , are involved in tissue matrix degradation and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g., osteoarthritis and rheumatoid arthritis, etc.), cerebral disease (e.g., stroke, etc.), tissue ulceration (e.g., corneal, epidermal and gastric ulcerations, etc.), abnormal wound healing, periodontal disease, bone disease (e.g., Paget ' s disease and osteoporosis, etc.), tumor metastasis or invasion and HIV-infection.
  • MMP-2, MMP-9 stromelysin
  • MMP-3 stromelysin
  • collagenase MMP-1, MMP-8, MMP-13
  • TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock.
  • R ⁇ is lower alkyl, halogen, optionally substituted heterocyclic group or optionally substituted aryl
  • R 2 is carboxy, protected carboxy or amidated carboxy
  • Ar is optionally substituted aryl or optionally substituted heterocyclic group
  • A is lower alkylene
  • X is oxa or a single bond
  • Y is thia, sulfinyl or sulfonyl
  • Z is methylene, thia, sulfinyl or sulfonyl
  • m and n are each an integer of 0 to 6, and l ⁇ m+n ⁇ 6, and its salt.
  • the object compounds of the present invention can be prepared by the following processes.
  • R2 , Ar, A, X, Y, Z, m and n are each as defined above,
  • R ,1i. is haloaryl or halo
  • R j is aryl
  • R ⁇ is aryl at least substituted by optionally substituted aryl, R ⁇ is aryl at least having carboxy moiety,
  • R! is aryl at least having amido moiety
  • Rf is aryl at least having amino moiety
  • R q is aryl at least having acylamino moiety
  • R ⁇ is aryl at least having protected amino moiety
  • R! is aryl at least having protected hydroxy moiety
  • RJ ⁇ is aryl at least having hydroxy moiety
  • R£ is aryl at least having thia moiety
  • R ⁇ - is aryl at least having sulfinyl or sulfonyl moiety
  • R ⁇ is aryl at least having formyl moiety
  • R! is aryl at least having hydroxymethyl moiety
  • R Q is aryl at least having vinyl moiety
  • R p is aryl at least having 1, 2-dihydroxyethyl moiety
  • R q is aryl at least having acyloxy moiety
  • R! is aryl at least having protected carboxy moiety
  • R g is aryl at least having halo (lower ) alkanoyl moiety
  • R ⁇ is aryl at least having substituted amino ( lower ) alkanoyl moiety
  • R a is protected carboxy
  • Rj5 is optically active amide
  • R is protected carboxy
  • R J is hydrogen or hydroxy-protective group
  • R is hydroxy-protective group
  • R 4 is optionally substituted aryl
  • R J and R° are each hydrogen or combmedtogether to form lower alkylene
  • Y a is thia, sulfinyl or sulfonyl
  • Z a is methylene, thia, sulfinyl or sulfonyl, provided that at least one of Y a and Z a is thia or sulfinyl
  • Yk is thia, sulfinyl or sulfonyl
  • Z is methylene, thia, sulfinyl or sulfonyl, provided that at least one of Y ⁇ and Z j -, is sulfinyl or sulfonyl
  • L is a leaving group
  • 1 is an integer of 1 to 6.
  • the starting compounds used in the above processes can be prepared according to the following Preparations or by a conventional method.
  • Suitable salts of the object compounds (I) to (I-ae) may be conventional non-toxic pharmaceutically acceptable salts and include an acid addition salt such as an organic acid salt (e.g., acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g., hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, etc.), or a salt with a base such as an amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.), an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g., trimethylamine salt, trieth
  • the object compounds and pharmaceutically acceptable salts thereof may include solvates such as enclosure compounds (e.g., hydrate, etc.).
  • lower is intended to mean up to 6 carbon atoms, preferably up to 4 carbon atoms, unless otherwise indicated.
  • Suitable "aryl” and aryl moiety in the term “optionally substituted aryl” may include an aryl having 6 to 10 carbon atoms, such as phenyl, tolyl, xylyl, cumenyl, mesityl, naphthyl and the like, preferably phenyl and naphthyl.
  • Suitable "optionally substituted aryl” may include above-mentioned aryl, which is substituted by the group consisting of the following (Al) to (A35);
  • heterocyclic group in the term “optionally substituted heterocyclic group” means saturated or unsaturated, monocyclic or polycyclic heterocyclic group containing at least one hetero atom such as oxygen atom, sulfur atom, nitrogen atom and the like.
  • heterocyclic groups are following (1) to (14) : (1) unsaturated 3- to 8-membered, preferably 5- or 6- membered, heteromonocyclic group containing 1 to 4 nitrogen atoms
  • unsaturated condensed (preferably bicyclic) 7- to 13-membered, preferably 9- or 10-membered, heterocyclic group containing 1 to 5 nitrogen atoms indolyl, isoindolyl, indolizinyl, benzimidazolyl , qinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl (e.g., tetrazolo[l,5-bJ pyridazinyl, etc.
  • oxazolyl isoxazolyl, oxadiazolyl (e.g., 1,2,4- oxadiazolyl, 1, 3, 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, etc.), and the like);
  • unsaturated condensed preferably bicyclic 7- to 13-membered, preferably 9- or 10-membered, heterocyclic group containing 1 or 2 oxygen atoms (benzofuranyl, benzodihydrofuranyl, benzodioxolenyl, and the like);
  • unsaturated condensed preferably bicyclic 7- to 13-membered, preferably 9- or 10-membered, heterocyclic group containing 1 or 2 sulfur atoms (benzothienyl, dihydrobenzothienyl, and the like);
  • heterocyclic groups may have one or more substituents.
  • substituents for substituted heterocyclic group may be the same as those for "optionally substituted aryl" (above-mentioned (Al) to (A35))
  • Suitable “lower alkyl” may include a straight or branched alkyl having 1 to 6 carbon atoms, and exemplified by methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl, pentyl, hexyl and the like, and the most preferably methyl for R .
  • Suitable “lower alkenyl” may include a straight or branched alkenyl having 2 to 6 carbon atoms, and exemplified by ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl and the like.
  • Suitable "lower alkoxy” may include a straight or branched alkenyl having 1 to 6 carbon atoms, and exemplified by methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, tert-pentyloxy, hexyloxy and the like.
  • Suitable "hydroxy-protective group” may include a conventional protective group, for example, substituted lower alkyl such as lower alkoxy (lower) alkyl (e.g., methoxymethyl) , lower alkoxy (lower) alkoxy (lower ) alkyl (e.g., methoxyethoxymethyl ) and substituted or unsubstituted aryl (lower ) alkyl (e.g., benzyl nitrobenzyl) ; acyl such as lower alkanoyl (e.g., acetyl, propionyl, pivaloyl), aroyl (e.g., benzoyl, fluorenecarbonyl ) , lower alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert- butoxycarbonyl, penty
  • benzyloxycarbonyl, bromobenzyloxycarbonyl) arenesulfonyl (e.g., benzenesulfonyl, tosyl) and alkanesulfonyl (e.g., methanesulfonyl, ethanesulfonyl ) ; tri (lower ) alkylsilyl (e.g. trimethylsilyl); tetrahydropyranyl; and the like, preferably tetrahydropyranyl.
  • Suitable "halogen” includes fluorine, bromine, chlorine and iodine.
  • acylamino includes acyl such as aliphatic acyl, aromatic acyl, heterocyclic acyl and aliphatic acyl substituted by aromatic or heterocyclic group (s) derived from carboxylic, carbonic, sulfonic and carbamic acids.
  • the aliphatic acyl includes saturated or unsaturated, acyclic or cyclic ones, for example, alkanoyl such as lower alkanoyl (e.g., formyl, acetyl, propionyl, butylyl, isobutylyl, valeryl, isovaleryl, pivaloyl, hexanoyl, etc.), alkylsulfonyl such as lower alkylsulfonyl (e.g., mesyl, ethylsulfonyl, propylsulfonyl , isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl , pentylsulfonyl , hexylsulfonyl, etc.), carbamoyl, N-alkylcarbamoyl (e.g., methylcarbamoyl, ethyl
  • the aromatic acyl may include Cg-C g aroyl (e.g., benzoyl, toluoyl, xyloyl, etc.), N- (Cg-C g) arylcarbamoyl (e.g., N-phenylcarbamoyl, N-tolylcarbamoyl, N-naphthylcarbamoyl, etc.), Cg-C g arenesulfonyl (e.g., benzenesulfonyl, tosyl, etc.), and the like.
  • Cg-C g aroyl e.g., benzoyl, toluoyl, xyloyl, etc.
  • N- (Cg-C g) arylcarbamoyl e.g., N-phenylcarbamoyl, N-tolylcarbamoyl, N-naphth
  • the heterocyclic acyl may include heterocyclic-carbonyl (e.g., furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl, tetrazolylcarbonyl, etc.), and the like.
  • heterocyclic-carbonyl e.g., furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl, tetrazolylcarbonyl, etc.
  • the aliphatic acyl substituted by aromatic group (s) may include aralkanoyl such as phenyl (lower ) alkanoyl (e.g., phenylacetyl, phenylpropionyl, phenylhexanoyl, etc.), aralkoxycarbonyl such as phenyl (lower) alkoxycarbonyl (e.g., benzyloxycarbonyl, phenethyloxycarbonyl, etc.), aryloxyalkanoyl such as phenoxy (lower) alkanoyl (e.g., phenoxyacetyl, phenoxypropionyl, etc.), and the like.
  • aralkanoyl such as phenyl (lower ) alkanoyl (e.g., phenylacetyl, phenylpropionyl, phenylhexanoyl, etc.)
  • the aliphatic acyl substituted by heterocyclic group (s) may include heterocyclic-alkanoyl such as heterocyclic- (lower) alkanoyl (e.g., thienylacetyl, imidazolylacetyl, furylacetyl, tetrazolylacetyl, thiazolylacetyl, thiadiazolylacetyl , thienylpropionyl, thiadiazolylpropionyl , etc.), and the like.
  • heterocyclic-alkanoyl such as heterocyclic- (lower) alkanoyl (e.g., thienylacetyl, imidazolylacetyl, furylacetyl, tetrazolylacetyl, thiazolylacetyl, thiadiazolylacetyl , thienylpropionyl, thiadiazolylpropionyl , etc.), and the like.
  • acyl groups may be further substituted by one or more suitable substituents as those for “optionally substituted aryl” (above-mentioned (Al ) to (A35)).
  • suitable “protected carboxy” includes esterified carboxy wherein “esterified carboxy” is as defined below.
  • ester moiety of the esterified carboxy are lower alkyl ester (e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, etc.) and the like, which may have at least one suitable substituent.
  • lower alkyl ester e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, etc.
  • substituted lower alkyl ester examples include lower alkanoyloxy (lower) alkyl ester [e.g., acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, l-(or 2-) acetoxyethyl ester, l-(or 2- or 3-) acetoxypropyl ester, l-(or 2- or 3- or 4-)- acetoxybutyl ester, 1- (or 2-) propionyloxyethyl ester, 1- (or 2- or 3-) propionyloxypropyl ester, l-(or 2-) - butyryloxyethyl ester, 1- (or 2-) isobutyryloxyethyl ester, l-(or 2-) pivaloyloxyethyl ester, l-(or 2-) hexanoyl este
  • More preferable example of the protected carboxy thus defined may be C -C ⁇ alkoxycarbonyl, and the most preferable one may be methoxycarbonyl, ethoxycarbonyl, and t-butoxycarbonyl for R 2 .
  • amidated carboxy may include optionally substituted carbamoyl such as -carbamoyl,
  • lower alkylcarbamoyl wherein the lower alkyl group may be the same as those mentioned above (e.g. methylcarbamoyl, ethylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, 3-methylbutylcarbamoyl, isobutylcarbamoyl, pentylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, etc.),
  • aryl (lower) alkyl ) carbamoyl such as phenyl (lower) - alkylcarbamoyl (e.g. 1-phenylethylcarbamoyl,
  • -lower alkylsulfonylcarbamoyl e.g. methylsulfonylcarbamoyl, etc.
  • -arenesulfonylcarbamoyl e.g. benzenesulfonylcarbamoyl, etc.
  • amidated carboxy thus defined may be :
  • Suitable “leaving group” may include halogen as mentioned above, acyloxy such as sulfonyloxy (e.g., mesyloxy, tosyloxy, etc.), alkoxy (e.g., tert-butoxy, etc.), aralkoxy (e.g., benzyloxy, etc.), and the like, preferably halogen and the most preferably bromine.
  • acyloxy such as sulfonyloxy (e.g., mesyloxy, tosyloxy, etc.), alkoxy (e.g., tert-butoxy, etc.), aralkoxy (e.g., benzyloxy, etc.), and the like, preferably halogen and the most preferably bromine.
  • Suitable "lower alkylene” may include straight or branched one such as methylene, ethylene, trimethylene, propylene, tetramethylene, ethylethylene, pentamethylene, hexamethylene, and the like, in which more preferable one may be C -C ⁇ alkylene, and the most preferable one may be ethylene, 1-methyltrimethylene, and trimethylene .
  • Suitable "halo (lower) alkyl” may be above-mentioned lower alkyl substituted by halogen as mentioned above, in which more preferable one may be halo (C -C ⁇ ) alkyl .
  • Suitable "halo (lower) alkoxy” may be above-mentioned lower alkoxy substituted by halogen as mentioned above, in which more preferable one may be halo (C -C ⁇ ) alkoxy .
  • Suitable "lower alkylthio” may be thio group substituted by above-mentioned lower alkyl, in which more preferable one may be C -C ⁇ alkylthio (e.g. methylthio, ethylthio, etc.) .
  • Suitable "lower alkylsulfinyl” may include methylsulfinyl, ethylsulfinyl, and the like, in which more preferable one may be C -C ⁇ alkylsulfinyl (e.g. methylsulfinyl, etc.).
  • Suitable "lower alkylsulfonyl” may include methylsulfonyl, ethylsulfonyl, and the like, in which more preferable one may be C ⁇ -C ⁇ alkylsulfonyl (e.g. methylsulfonyl, etc.).
  • Suitable "haloaryl may be aforementioned aryl substituted by halogen as mentioned above, in which more preferable one may be halo (Cg-C g ) ryl, and the most preferable one may be 4-fluorophenyl .
  • Suitable "hydroxy (lower ) alkyl” may be above-mentioned lower alkyl substituted by hydroxy as mentioned above, in which more preferable one may be hydroxy (C ⁇ -C ⁇ ) alkyl .
  • Suitable "protected hydroxy (lower ) alkyl” may be above- mentioned hydroxy (lower) alkyl group protected by a conventional hydroxy-protective group such as acyl, (lower alkyl) (diaryl) silyl group (e.g. (t-butyl ) (diphenyl) silyl, etc.), and the like.
  • Suitable "aryl (lower) alkoxy” may include benzyloxy, phenylethoxy, and the like, in which more preferable one may be phenyl (C ⁇ -C ⁇ ) alkoxy (e.g. benzyloxy, etc.).
  • Suitable “carbamoyl (lower) alkenyl” may include carbamoylethenyl, carbamoylallyl, and the like, in which more preferable one may be carbamoyl (C2-C4 ) alkenyl (e.g. carbamoylethenyl, etc.).
  • Suitable "lower alkoxyaryl” may include methoxyphenyl, ethoxyphenyl, and the like, in which more preferable one may be C -C ⁇ alkoxyphenyl (e.g. methoxyphenyl, etc.).
  • Carbamoyl (lower ) alkenyl optionally N-substituted by the group consisting of lower alkyl, aryl, lower alkoxyaryl and haloaryl may include lower alkylcarbamoyl (lower ) alkenyl (e.g. carbamoylethenyl, methylcarbamoylethenyl, ethylcarbamoylethenyl, propylcarbamoylethenyl, isopropycarbamoylethenyl, dimethylcarbamoylethenyl, etc.), Cg-C g arylcarbamoyl (lower ) alkenyl (e.g.
  • phenylcarbamoylethenyl, etc. lower alkoxy (Cg-C 0 ) arylcarbamoyl (lower ) alkenyl (e.g. methoxyphenylcarbamoylethenyl, etc.), haloarylcarbamoyl (lower) alkenyl (e.g. fluorophenylcarbamoylethenyl, etc.), and the like.
  • Suitable "lower alkylaminocarbonyloxy” may include methylammocarbonyloxy, ethylaminocarbonyloxy, and the like, in which more preferable one may be C -C ⁇ alkylaminocarbonyloxy (e.g. methylammocarbonyloxy, ethylaminocarbonyloxy, etc.).
  • Suitable "lower alkanoyloxy” may include acetyoxy, propanoyloxy, and the like, in which more preferable one may be C ⁇ -C ⁇ alkanoyloxy (e.g. propanoyloxy, etc.).
  • Suitable "lower alkoxy (lower ) alkanoyloxy” may include methoxyacetyloxy, ethoxyacetyloxy, and the like, in which more preferable one may be C -C ⁇ alkoxy (C ⁇ -C ⁇ ) alkanoyloxy (e.g. methoxyacetyloxy, etc.).
  • Suitable "lower alkoxycarbonyloxy” may include methoxycarbonyloxy, ethoxycarbonyloxy, and the like, in which more preferable one may be C ⁇ -C ⁇ alkoxycarbonyloxy (e.g. ethoxycarbonyloxy, etc.).
  • Suitable "lower alkenoyloxy” may include acryloyloxy, and the like, in which more preferable one may be C 2 -C ⁇ alkenoyloxy (e.g. acryloyloxy, etc.).
  • lower alkenoyloxy optionally substituted by heterecyclic group may include lower alkenoyloxy optionally substituted by the above-mentioned heterocyclic group (1) (e.g. pyridyl, etc.) such as pyridylacryloyloxy, and the like.
  • heterocyclic group (1) e.g. pyridyl, etc.
  • Suitable "lower cycloalkanecarbonyloxy” may include C3-C7 cycloalkanecarbonyloxy such as cyclopropanecarbonyloxy, cyclobutanecarbonyloxy, and the like, in which more preferable one may be C ⁇ -Cg alkanecarbonyloxy (e.g. cyclopropanecarbonyloxy, etc.).
  • Suitable "lower cycloalkanecarbamoyl” may include C3-C-7 cycloalkanecarbamoyl such as cyclopropanecarbamoyl, cyclobutanecarbamoyl, and the like, in which more preferable one may be C ⁇ -Cg cycloalkanecarbamoyl (e.g. cyclopropanecarbamoyl, etc.).
  • Suitable "lower alkylcarbamoyl” may include methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl and the like, in which more preferable one may be C -C ⁇ alkylcarbamoyl (e.g. methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, etc.).
  • lower alkoxy substituted by the group consisting of carboxy, protected carboxy, lower alkanoyl, lower cycloalkanecarbamoyl, lower alkylcarbamoyl may include arboxy (lower ) alokoxy (e.g. carboxymethoxy, etc.), lower alkoxycarbonyl (lower ) alkoxy (e.g. ethoxycarbonylmethoxy, butoxycarbonylmethoxy, etc.), lower alkanoyl (lower) alkoxy (e.g. propanoylmethoxy, etc.), lower cycloalkanecarbamoyl (lower) alkoxy (e.g.
  • cyclopropylcarbamoylmethoxy, etc. loweralkylcarbamoyl (lower) alkoxy (e.g. methylcarbamoylmethoxy, ethylcarbamoylmethoxy, propylcarbamoylmethoxy, etc.), and the like.
  • Suitable "lower alkylcarbamoyloxy (lower) alkyl” may include methylcarbamoyloxymethyl, ethylcarbamoyloxymethyl, and the like, in which more preferable one may be C -C ⁇ alkylcarbamoyloxy (C -C ⁇ ) alkyl (e.g. methylcarbamoyloxymethyl, etc. ) .
  • Suitable "lower alkoxycarbonylamino (lower) alkyl” may include methoxycarbonylaminomethyl, t-butoxycarbonylaminomethyl, and the like, in which more preferable one may be C -C j alkoxycarbonylamino (C -C ⁇ ) alkyl (e.g. methoxycarbonylaminomethyl, t-butoxycarbonylaminomethyl, etc.) .
  • Suitable “amino (lower) alkyl” may include aminomethyl, aminoethyl, and the like, in which more preferable one may be amino (C -C ⁇ ) alkyl (e.g aminomethyl, etc.).
  • Suitable "lower alkylcarbamoyl (lower ) alkyl” may include methylcarbamoylmethyl, methylcarbamoylethyl, ethylcarbamoylmethyl, ethylcarbamoylethyl, and the like, in which more preferable one may be C -C ⁇ alkylcarbamoyl- (C -C4)alkyl (e.g. methylcarbamoylmethyl, etc.).
  • Suitable “heterocyclic-carbonylamino” may include carbonylamino group substituted by the above-mentioned heterocyclic group (2), (4) and (5) (e.g. pyrrolidinyl, teretahydroisoquinolyl, furyl, etc.) such as pyrrolidinylcarbonylamino, 1,2,3,4- teretahydroisoquinolylcarbonylamino, furylcarbonylammo, and the like.
  • heterocyclic-carbonylamino may include above-mentioned heterocyclic-carbonylamino optionally the heterocyclic group being substituted by N-protective group (e.g. acyl such as alkoxycarbonyl, etc.) such as pyrrolidinylcarbonylamino, 1,2,3, 4-teretahydroisoquinolylcarbonylamino, (N- (t- butoxycarbonyl) -1,2,3, 4-teretahydroisoquinolyl) - carbonylamino, furylcarbonylammo, and the like.
  • N-protective group e.g. acyl such as alkoxycarbonyl, etc.
  • pyrrolidinylcarbonylamino 1,2,3, 4-teretahydroisoquinolylcarbonylamino
  • Suitable "nitro (lower) alkenyl” may be above-mentioned lower alkenyl substituted by nitro, in which more preferable one may be nitro (C2-C4 ) alkenyl .
  • Suitable "lower alkylenedioxy” may include straight or branched one such as methylenedioxy, ethylenedioxy, trimethylenedioxy, propylenedioxy, tetramethylenedioxy, ethylethylenedioxy, pentamethylenedioxy, hexamethylenedioxy, and the like, in which more preferable one may be C -C ⁇ alkylenedioxy .
  • Suitable “amido” may be the same as those for “amidated carboxy”, and preferably lower alkylcarbamoyl, and the most preferably methylcarbamoyl.
  • acylamino may be amino substituted by acyl as mentioned above.
  • Suitable “substituted amine” may include amino group substituted by the above-mentioned substituent (A2) to (A12), (A14) to (A17), (A20) to (A32) and (A34).
  • Preferable examples may be hydroxy (lower) alkylamine (e.g. hydroxyethylamine, etc.), above-mentioned N-containing heterocyclic group (e.g. morpholino, etc.), lower alkenylamine (e.g. allylamine, etc.), Cg-C g aryl (lower) alkylamine e.g. benzylamine, etc.), lower alkylamine (e.g. t-butylamine, pentylamine, etc.), heterocyclic (lower) alkylamine such as pyridyl (lower) alkylamine (e.g. pyridylmethylamine, etc.), lower alkoxy (lower) alkylamine (e.g. ethoxyethylamine, etc.), and the like.
  • heterocyclic (lower) alkylamine such as pyridyl (lower) alkylamine (e.g. pyridylmethyl
  • the preferred one may be the compounds (I) wherein m and n are each 0 or 1, and (ii) the more preferred one may be the compounds of the above item (i) wherein A is ethylene,
  • trimethylene 1-methyltrimethylene, or trimethylene .
  • the more preferred object compounds (I) are:
  • R ,1 i s lower alkyl, phenyl, halophenyl, or
  • R is carboxy or hydroxyaminocarbonyl
  • m and n are each an integer of 0 or 1
  • m+n l
  • R is halogen; heterocyclic group consisting of pyridyl, thienyl, furyl, benzofuranyl or benzothienyl , wherein the heterocyclic group is optionally substituted by the group consisting of lower alkanoyl, lower alkyl, lower alkoxy, lower alkoxycarbonylamino and lower alkylcarbamoyl; naphtyl or phenyl optionally substituted by the group consisting of the following (Cl) to (C31);
  • R is hydroxyaminocarbonyl, m is 0 and n is 1,
  • a group of the formula is one of the group of the following formulae (a) to (e) ;
  • R is halo (e.g. bromo, etc.), naphtyl (e.g. 2-naphthyl, etc.), phenyl (e.g. phenyl, etc.), mono- or dihalophenyl (e.g. 3 (or 4 ) -chlorophenyl, 2 (or 3 or
  • lower alkylcarbamoylphenyl e.g. 4-methylcarbamoylphenyl, 4-ethylcarbamoylphenyl, etc.
  • carbamoylphenyl e.g. 4-carbamoylphenyl, etc.
  • phenyl (lower ) alkylcarbamoylphenyl e.g. 4- benzylcarbamoylphenyl, etc.
  • lower alkanoylphenyl e.g.
  • lower alkylendioxyphenyl e.g. 3, 4-methylendioxyphenyl, etc.
  • lower alkanesulfonylaminophenyl e.g. 4- (methanesulfonylamin
  • phenyl (lower) alkoxyphenyl e.g. 4-benzyloxyphenyl, etc.
  • carbamoyl (lower ) alkenylphenyl, mono- or di (lower alkyl) carbamoyl (lower) alkenylphenyl e.g. 4- (2- (methylcarbamoyl) ethenyl) phenyl, 4- (2- (ethylcarbamoyl ) ethenyl) phenyl, 4- (2- (propylcarbamoyl) ethenyl ) phenyl,
  • R 12 is lower alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, neopentyl, etc.) optionally substituted by the group consisting of phenyl (e.g. phenyl, etc.), halophenyl (e.g. 4-chlorophenyl, etc.), lower alkoxyphenyl (e.g. 4-methoxyphenyl, etc.), lower alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, isopropyloxy, etc.), phenoxy (e.g.
  • phenoxy, etc. lower alkoxyphenoxy (e.g. 3 (or 4 ) -methoxyphenoxy, etc.), halophenoxy (e.g. 4-fluoro(or chloro) phenoxy, etc.), lower alkylphenoxy (e.g. 3 (or 4)- methylphenoxy, etc.), carboxy (e.g. carboxy, etc.), lower alkoxycarbonyl (e.g. methoxycarbonyl, t- butoxycarbonyl, etc.), lower alkylcarbamoyl (e.g. methylcarbamoyl, etc.), halo (e.g. chloro, etc.), lower alkenyloxy (e.g.
  • allyloxy etc. lower alkoxy (lower) alkoxy (e.g. 2-ethoxyethoxy, etc.), phenyl (lower ) alkoxy (e.g. benzyloxy, etc.), piperidinyloxy (e.g. 4-piperidinyloxy, etc.), N-t- butoxycarbonylpiperidinyloxy (e.g. N-t- butoxycarbonyl-4-piperidinyloxy, etc.), pyridyloxy (e.g. 3 (or 4 ) -pyridyloxy, etc.), hydroxy (e.g. hydroxy, etc.), lower alkanoyloxy (e.g.
  • acetoxy etc. mono- or di (lower) alkylcarbamoyloxy (e.g. methylcarbamoyloxy, N-methyl-N-ethylcarbamoyloxy, etc.), piperidinylcarbonyloxy (e.g. piperidinocarbonyloxy, etc.), phenyl (lower) alkylcarbamoyloxy (e.g. benzylcarbamoyloxy, etc.), lower alkoxycarbonylammo (e.g. methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, t- butoxycarbonylamino, etc.), amino (e.g.
  • lower alkoxycarbonylammo e.g. methoxycarbonylamino, t-butoxycarbonylamino, etc.
  • fluorenylmethoxycarbonylamino e.g. fluorenylmethoxycarbonylamino etc.
  • mono- or di (lower) alkylamino e.g. methylamino ethylamino dimethylamino, N-methyl-N-ethylamino t-butylamino, pentylamino etc.
  • N-lower alkyl-N- (lower alkoxycarbonyl) amino e.g.
  • methanesulfonylamino, etc. lower alkoxy (lower) alkanoylamino (e.g. methoxyacetylamino, etc.), cyclo (lower) alkyloxycarbonylamino (e.g. cyclopentyloxycarbonylamino, etc. ) , pyridylcarbonylamino (e.g. pyridylcarbonylamino, etc.), morpholinocarbonylamino (e.g. morpholinocarbonylamino, etc.), phenyl (lower) alkoxycarbonylamino (e.g.
  • benzyloxycarbonylamino, etc. lower alkoxyphenylsulfonylamino (e.g. 4- methoxyphenylsulfonylamino, etc. ) , hydroxy (lower) alkylamino (e.g. 2-hydroxyethylamino, etc.), morpholino (e.g. morpholino, etc.), oxooxazolidinyl (e.g. 2-oxo-l , 3-oxazolidin-l-yl, etc.), oxopyrrolidinyl (e.g. 2-oxopyrrolidin-l-yl, etc.), trimethylhydantoinyl (e.g.
  • M is oxygen or sulfur
  • R 13 is lower alkyl (e.g. methyl, ethyl, propyl, isopropyl, etc.), phenyl (lower) alkyl (e.g. benzyl, etc.), lower alkoxy (lower ) alkyl (e.g.
  • 2-methoxyethyl, etc. 2-methoxyethyl, etc.), halo (lower) alkyl (e.g 2-choloroethyl, etc.), amino (lower) alkyl, phthalimido (lower) alkoxycarbonylammo (e.g. 2- aminoethyl, 2-phthalimidoethyl, etc.), lower alkenyl (e.g. allyl, etc.), phenyl (e.g. phenyl, etc . ) ,
  • 15 is hydrogen, or lower alkyl (e.g. methyl, etc.)
  • 14 is hydrogen, lower alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, etc.), naphthyl (e.g. 1-naphthyl, etc.), halophenyl (e.g. 3 (or 4 ) -chlorophenyl etc.), lower alkoxyphenyl (e.g. 4-methoxyphenyl, etc.), lower alkenyl (e.g. allyl, etc.), cyclo (lower) alkyl (lower) alkyl (e.g.
  • cyclohexylmethyl, etc. phenyl (lower) alkyl (e.g. benzyl, etc.), halo (lower ) alkyl (e.g. 2-chloroethyl, etc.), lower alkoxy (lower ) alkyl (e.g. methoxymethyl, 2-methoxyethyl, etc.), hydroxy (lower) alkyl (e.g. 2- hydroxyethyl, etc.), (lower alkyl) (diphenyl) silyloxy (lower ) alkyl (e.g.
  • R 16 i s benzothienyl (e.g. 2-benzoth ⁇ enyl, etc.), benzofuranyl (e.g. 2-benzofuranyl, etc.), thienyl
  • Rl wherein R 12 is lower alkyl, phenyl (lower) alkyl, halophenyl (lower) alkyl , lower alkoxyphenyl (lower) alkyl, lower alkoxy (lower) alkyl, phenoxy (lower) alkyl, lower alkoxyphenoxy (lower) alkyl, halophenoxy (lower) alkyl, lower alkylphenoxy (lower) alkyl, carboxy (lower) alkyl, lower alkoxycarbonyl (lower) alkyl, lower alkylcarbamoyl (lower) alkyl, halo (lower ) alkyl, lower alkenyloxy (lower) alkyl, lower alkoxy (lower) alkoxy (lower) alkyl, phenyl (lower) alkoxy (lower ) alkyl, piperidinyloxy (lower) alkyl,
  • amino (lower alkoxy) (lower) alkyl (e.g. l-amino-2- methoxyethyl, etc.), (lower alkoxycarbonylamino) -
  • (lower) alkyl e.g. l-amino-3-carboxypropyl, 1-t- butoxycarbonylamino-3-carboxypropyl, l-amino-3- (t- butoxycarbonyl ) propyl, l-t-butoxycarbonylamino-3-t- butoxycarbonylpropyl, etc.
  • amino (phenyl (lower ) alkoxy) (lower) alkyl, (lower alkoxycarbonylamino) (phenyl (lower) alkoxy) - (lower) alkyl (e.g. l-amino-2-benzyloxyethyl, 1-t- butoxycarbonylamino-2-benzyloxyaminoethyl, etc. ) ,
  • amino (pyridyl) (lower) alkyl, (lower alkoxycarbonylamino) (pyridyl) (lower) alkyl (e.g. 1- amino-2- (3-pyridyl ) ethyl, 1-t-butoxycarbonylamino- 2- (3-pyridyl) ethyl, l-amino-2- (4-pyridyl) ethyl, 1- t-butoxycarbonylamino-2- (4-pyridyl) ethyl, etc. ) ,
  • amino) (hydroxy) (lower) alkyl, (lower alkoxycarbonylamino) (hydroxy) (lower) alkyl e.g. 1- amino-2-hydroxyethyl, 1-t-butoxycarbonylamino-2- hydroxyethyl, etc.
  • amino) (amino) (lower ) alkyl e.g. 1- amino-2-hydroxyethyl, 1-t-butoxycarbonylamino-2- hydroxyethyl, etc.
  • amino) (amino) (lower ) alkyl e.g. 1- amino-2-hydroxyethyl, 1-t-butoxycarbonylamino-2- hydroxyethyl, etc.
  • amino) (amino) (lower ) alkyl e.g. 1- amino-2-hydroxyethyl, 1-t-butoxycarbonylamino-2- hydroxyethyl, etc.
  • amino) (amino) (lower ) alkyl e.g. 1- amino
  • R 11 is bromo, 2-naphthyl, phenyl,
  • R 12 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, neopentyl, phenylmethyl,
  • 14 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, 1-naphthyl, 3 (or ) -chlorophenyl, 3-methoxyphenyl, allyl, cyclohexylmethyl, benzyl, 2-chloroethyl, methoxymethyl, 2-methoxyethyl, 2-hydroxyethyl, 2- ( (t-butyl) (diphenyl) silyloxy) ethyl, carboxymethyl, ethoxycarbonylmethyl, methylcarbamoylmethyl, or 3-pyridyl,
  • R 14 is ethyl and R 15 is methyl
  • R 16 is 2-benzothienyl, 2-benzofuranyl , 2 (or 3) -thienyl, 2-furyl, 3-pyridyl, l-methyl-4-pyridyl , 6-methyl-3- pyridyl, 6-methoxy-3-pyridyl, 5-methoxycarbonyl mino-3-pyridyl, 5-acetyl-2-thienyl, 2-methylcarbamoyl-5-benzofuranyl .
  • the object compound (I-b) or a salt thereof can be prepared by subjecting a compound (I-a) or a salt thereof to removal reaction of the carboxy-protective group.
  • Suitable salts of the compounds (I-a) and (I-b) can be referred to the ones as exemplified for the compound (I) .
  • This reaction is carried out in accordance with a conventional method such as solvolysis including hydrolysis, reduction or the like.
  • Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, lithium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, hydrazine, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1, 5-diazabicyclo [ 4.3.0] - non-5-ene, l,4-diazabicyclo[2.2.2]octane, 1, 8-diazabicyclo [5.4.0] undec-7-ene, or the like.
  • an alkali metal e.g. sodium, lithium, potassium, etc.
  • an alkaline earth metal e.g. magnesium, calcium, etc.
  • the hydroxide or carbonate or bicarbonate thereof hydrazine
  • trialkylamine e.g. trimethylamine, triethylamine, etc.
  • picoline 1,
  • Suitable acid may include and organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, hydrogen fluoride, boron trifluoride diethyl etherate, hydrogen iodide, etc.].
  • the removal reaction using Lewis acid such as trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like, is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].
  • the reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, chloroform, carbon tetrachloride, dioxane, tetrahydrofuran, N, N-dimethylformamide, a mixture thereof or any other solvent which does not adversely influence the reaction.
  • a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, chloroform, carbon tetrachloride, dioxane, tetrahydrofuran, N, N-dimethylformamide, a mixture thereof or any other solvent which does not adversely influence the reaction.
  • a liquid base or acid can be also used as the solvent.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
  • the reduction method applicable for the removal reaction may include chemical reduction and catalytic reduction.
  • Suitable reducing agents to be used in chemical reduction may include a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].
  • metal e.g. tin, zinc, iron, etc.
  • metallic compound e.g. chromium chloride, chromium acetate, etc.
  • organic or inorganic acid e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel catalysts [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like, and these catalysts may be used in a combination with ammonium formate (e.g. a combination of palladium on carbon and ammonium formate, etc. ) .
  • platinum catalysts
  • the reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N, N-dimethylformamide, or a mixture thereof.
  • a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.
  • reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to heating.
  • the compound (I-b) or a salt thereof can be prepared by oxidating the compound (II) or a salt thereof. Suitable salts of the compound (II) may be the same as those for the compound (I) .
  • Oxidation is carried out in a conventional manner, which is capable of oxidating a vinyl group to a carboxy group
  • suitable oxidizing reagent may be oxygen acid such as periodate (e.g. sodium periodate, potassium periodate, etc.), peroxy acid such as perbenzoic acid (e.g., perbenzoic acid, m-chloroperbenzoic acid, etc.), OXONE ⁇ KHSO ⁇ -KHSO ⁇ -f ⁇ SO ⁇ ) , potassium permanganate, a combination of titanium (III) chloride and hydrogen peroxide, a combination thereof (e.g. a combination of potassium permanganate and sodium periodate, etc.), and the like.
  • oxygen acid such as periodate (e.g. sodium periodate, potassium periodate, etc.), peroxy acid such as perbenzoic acid (e.g., perbenzoic acid, m-chloroperbenzoic acid, etc.), OXONE ⁇ KHSO ⁇ -KHSO ⁇ -f ⁇ SO
  • This reaction can be carried out in the presence of a suitable base as mentioned above (e.g. potassium carbonate, etc. ) .
  • a suitable base e.g. potassium carbonate, etc.
  • the reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.), tetrahydrofuran, dioxane, dichloromethane, ethylene dichloride, chloroform, N, N-dimethylformamide, N, N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction,
  • alcohol e.g., methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.
  • tetrahydrofuran dioxane
  • dichloromethane ethylene dichloride
  • chloroform N, N-dimethylformamide, N, N-dimethylacetamide, or any other organic
  • hydrophilic solvents may be used in a mixture with water.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
  • the compound (I-d) or a salt thereof can be prepared by subjecting the compound (I-c) or a salt thereof to a reduction reaction. Suitable salts of the compounds (I-c) and (I-d) may be the same as those for the compound (I) .
  • the reduction method applicable for this reaction may be the same as Process 1, which is capable of converting haloaryl group to aryl group (e.g. a combination of palladium on carbon and ammonium formate, etc.).
  • the compound (I-e) or a salt thereof can be prepared by reacting the compound (I-b) or its reactive derivative at the carboxy group, or a salt thereof with compound (IV) or its reactive derivative at the amino group, or a salt thereof .
  • Suitable reactive derivative at the amino group of the compound (IV) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (IV) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (IV) with a silyl compound such as bis (trimethylsilyl ) acetamide, mono (trimethylsilyl ) acetamide, bis (trimethylsilyl ) urea or the like; a derivative formed by reaction of the compound (IV) with phosphorus trichloride or phosgene, and the like.
  • Suitable salts of the compound (IV) and its reactive derivative can be referred to the acid addition salts as exemplified for the compound (I) .
  • Suitable salts of the compound (I-e) may be the same as those for the compound (I).
  • Suitable reactive derivative at the carboxy group of the compound (I-b) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.
  • Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride which acid such as substituted phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g.
  • cyanomethyl ester methoxymethyl ester, dimethyliminomethyl ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2 , 4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester,
  • N-hydroxy compound e.g. N, N-dimethylhydroxylamine, l-hydroxy-2- ( IH) - pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-lH-benzotriazole, etc.
  • reactive derivatives can optionally be selected from them according to the kind of the compound (I-b) to be used.
  • the reaction is usually carried out in a conventional solvent such as water, alcohol [e.g.
  • the reaction when the compound (I-b) is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N, N ' -dicyclohexylcarbodiimide; N-cyclohexyl-N ' -morpholinoethylcarbodiimide; N-cyclohexyl-N ' - (4-diethylaminocyclohexyl) carbodiimide; N, N ' -diethylcarbodiimide, N,N' -diisopropylcarbodiimide; l-ethyl-3- (3-dimethylaminopropyl) carbodiimide (WSCD) ; N, N ' -carbonylbis (2-methylimidazole) ; pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; e
  • N-hydroxybenzotriazole 1- (p-chlorobenzenesulfonyloxy) -6- chloro-lH-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N, N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like.
  • the reaction may also be carried out in the presence of an inorganic or organic base as mentioned above such as an alkali metal bicarbonate, tri (lower) alkylamine, pyridine, N- (lower) alkylmorpholine, N, -di (lower) alkylbenzylamine, alkali metal hydroxide, or the like.
  • an inorganic or organic base such as an alkali metal bicarbonate, tri (lower) alkylamine, pyridine, N- (lower) alkylmorpholine, N, -di (lower) alkylbenzylamine, alkali metal hydroxide, or the like.
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
  • the object compound (I-f) or a salt thereof can be prepared by cyclizing the compound (III) or a salt thereof. Suitable salts of the compounds (I-f) and (III) may be the same as those for the compound (I) .
  • This reaction is preferably carried out in the presence of hydrogen halide (e.g. hydrogen iodide, etc.) or alkali metal halide (e.g. sodium iodide, etc.).
  • hydrogen halide e.g. hydrogen iodide, etc.
  • alkali metal halide e.g. sodium iodide, etc.
  • This reaction can be carried out in the presence of a suitable base as mentioned above such as alkali metal hydroxide.
  • the reaction can be carried out in a conventional solvent, which does not adversely influence the reaction as mentioned above such as water, tetrahydrofuran, alcohol (e.g, methanol, ethanol, etc.), a mixture thereof, and the like.
  • a conventional solvent which does not adversely influence the reaction as mentioned above
  • alcohol e.g, methanol, ethanol, etc.
  • the reaction temperature is not critical and the reaction can be carried out under from warming to heating.
  • the compound (I-g) or a salt thereof can be prepared by reacting the compound (I-b) or its reactive derivative at the carboxy group, or a salt thereof, with an optically active amine or its reactive derivative at the amino group, or a salt thereof.
  • Suitable "optically active amine” may include a conventional one which is capable of separating the starting racemic compound into each optically active compound such as (R) - (+) - ⁇ -methylbenzylamine, and the like.
  • Suitable salts of the compound (I-g) may be the same as those exemplified for the compound (I) .
  • Suitable salts of the optically active amine may be acid addition salts as mentioned for the compound (I) .
  • the reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N, -dimethylformamide, pyridine and dichloromethane, a mixture thereof, or any other organic solvents which do not adversely affect the reaction .
  • a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N, -dimethylformamide, pyridine and dichloromethane, a mixture thereof, or any other organic solvents which do not adversely affect the reaction .
  • This reaction can be carried out in the presence of an organic or inorganic base such as alkali metal (e.g. lithium, sodium, potassium, etc.), alkaline earth metal (e.g., calcium, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkaline earth metal hydride (e.g., calcium hydride, etc.), alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), alkali metal bicarbonate (e.g., sodium bicarbonate, potassium bicarbonate, etc.), alkali metal alkoxide (e.g., sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.), alkali metal alkanoic acid (e.g., sodium acetate, etc.), trialkylamine (e.g., triethylamine, etc.),
  • Suitable reactive derivative at the amino group of optically active amine may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the said amine with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the said amine with a silyl compound such as bis (trimethylsilyl ) acetamide, mono (trimethylsilyl) acetamide, bis (trimethylsilyl) urea or the like; a derivative formed by the reaction of the said amine with phosphorus trichloride or phosgene, and the like.
  • Suitable reactive derivative at the carboxy group and salts of the compound (I-b) may be the same as mentioned above .
  • reaction is preferably carried out in the presence of a conventional condensing agent such as
  • 1-alkoxy-l-chloroethylene 1-alkoxy-l-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride) ; phosphorus trichloride; diphenyl phosphorylazide; thionyl chloride; oxalyl chloride; lower alkyl haloformate
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
  • Process 7 The compound (I-i) or a salt thereof can be prepared by subjecting the compound (I-h) or a salt thereof to a removal reaction of the hydroxy protective group.
  • Suitable salts of the compounds (I-h) and (I-i) may be the same as those exemplified for the compound (I) .
  • the reaction of this process can be carried out in a manner similar to that in Process 1.
  • the compound (I-k) and a salt thereof can be prepared by oxidating the compound (I-j) or a salt thereof.
  • Suitable salts of the compounds (I-j) and (I-k) may be the same as those exemplified above with regard to the compound ( I ) .
  • Suitable method of this oxidation includes conventional ones, which can convert thia group to sulfinyl or sulfonyl group, or sulfinyl to sulfonyl group, such as exemplified for Process 2.
  • the compound ( l-l) or a salt thereof can be prepared by reacting the compound (I-c) or a salt thereof with the compound (V) .
  • Suitable salts of the compound ( I- ) may be the same as those exemplified for the compound (I).
  • the reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, pyridine and dichloromethane, a mixture thereof, or any other organic solvents which do not adversely affect the reaction .
  • This reaction can be carried out in the presence of an organic or inorganic base such as alkali metal (e.g., lithium, sodium, potassium, etc.), alkaline earth metal (e.g., calcium, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkaline earth metal hydride (e.g., calcium hydride, etc.), alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), alkali metal bicarbonate (e.g., sodium bicarbonate, potassium bicarbonate, etc.), alkali metal alkoxide (e.g., sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.), alkali metal alkanoic acid (e.g., sodium acetate, etc.), trialkylamine (e.g., triethylamine, etc.),
  • alkali metal halide e.g., sodium iodide, potassium iodide, etc.
  • alkali metal thiocyanate e.g., sodium thiocyanate, potassium thiocyanate, etc.
  • di (lower) alkyl azodicarboxylate e.g., diethyl azodicarboxylate, diisopropyl azodicarboxylate,
  • the reaction is preferably carried out in the presence of a conventional condensing agent such as N, N ' -dicyclohexylcarbodiimide;
  • the reaction temperature is not critical, and the reaction is usually carried out under from warming to heating .
  • the compound (I-m) or a salt thereof can be prepared by reacting the compound (VI) or a salt thereof with the compound (VII) or a salt thereof.
  • Suitable salts of the compound (I-m) may be the same as those exemplified for the compound (I) .
  • reaction of this process can be carried out in a manner similar to that in Process 9.
  • the compound (I-n) or a salt thereof can be prepared by cyclizing the compound (VIII) or a salt thereof.
  • Suitable salts of the compounds (I-n) and (VIII) may be the same as those exemplified for the compound (I) .
  • This reaction can be carried out in the presence of a suitable acid as exemplified for Process 1, wherein preferable one may be trifluoroacetic acid, and the like.
  • the reaction can be carried out in a conventional solvent, which does not adversely influence the reaction as mentioned above such as water, tetrahydrofuran, alcohol (e.g. methanol, ethanol, etc.), a mixture thereof, and the like.
  • a conventional solvent which does not adversely influence the reaction as mentioned above such as water, tetrahydrofuran, alcohol (e.g. methanol, ethanol, etc.), a mixture thereof, and the like.
  • the reaction temperature is not critical and the reaction can be carried out under cooling to warming.
  • Process 12 The compound (I-o) or a salt thereof can be prepared by reacting the compound (IX) or a salt thereof with the compound (X) .
  • Suitable salts of the compounds (I-o) and (IX) may be the same as those exemplified for the compound (I) .
  • This reaction can be carried out in the presence of a suitable acid as exemplified for Process 1, wherein preferable one may be boron trifluoride diethyl etherate, and the like.
  • the reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, pyridine and dichloromethane, a mixture thereof, or any other organic solvents which do not adversely affect the reaction.
  • the reaction temperature is not critical and the reaction can be carried out under cooling to warming.
  • the compound (I-q) or a salt thereof can be prepared by amidating the compound (I-p) or its reactive derivative at the carboxy group, or a salt thereof.
  • Suitable salts of the compounds (I-p) and (I-q) may be the same as those for the compound (I) .
  • Suitable reactive derivative of the compound (I-p) may be the same as those for the compound (I-b) .
  • the amidation reaction applicable to this process may include a conventional amidation reaction which can convert a carboxy-group to an amido-group, for example, reaction with an optionally substituted amines such as mono- or di (lower ) alkylamine (e.g. methylamine, etc.), and the like.
  • an optionally substituted amines such as mono- or di (lower ) alkylamine (e.g. methylamine, etc.), and the like.
  • the compound (I-s) or a salt thereof can be prepared by acylating the compound (I-r) or its reactive derivative at the amino group, or a salt thereof. Suitable salts of the compounds (I-r) and (I-s) may be the same as those for the compound (I) .
  • Suitable acylating agent used in this reaction may be a conventional acylating agent which is capable of introducing the acyl group as mentioned before such as carboxylic acid, carbonic acid, sulfonic acid and their reactive derivative, for example, an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.
  • reactive derivative may include acid chloride, acid bromide, a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g.
  • dialkylphosphoric acid phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.
  • dialkylphosphorous acid sulfurous acid, thiosulfuric acid, sulfuric acid, alkyl carbonate (e.g. methyl carbonate, ethyl carbonate, propyl carbonate, etc.), aliphatic carboxylic acid (e.g. pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.), aromatic carboxylic acid (e.g.
  • benzoic acid etc.
  • a symmetrical acid anhydride an activated acid amide with a heterocyclic compound containing imino function such as imidazole, 4-substituted imidazole, dimethylpyrazole, triazole and tetrazole, an activated ester (e.g.
  • This reaction can be carried out in the presence of an organic or inorganic base such as alkali metal (e.g. lithium, sodium potassium, etc.), alkaline earth metal (e.g. calcium, etc.), alkali metal hydride (e.g. sodium hydride, etc.), alkaline earth metal hydride (e.g. calcium hydride, etc.), alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkali metal bicarbonate (e.g. sodium bicarbonate, potassium bicarbonate, etc.), alkali metal alkoxide (e.g.
  • alkali metal e.g. lithium, sodium potassium, etc.
  • alkaline earth metal e.g. calcium, etc.
  • alkali metal hydride e.g. sodium hydride, etc.
  • alkaline earth metal hydride e.g. calcium hydride, etc.
  • alkali metal alkanoic acid e.g. sodium acetate, etc.
  • trialkylamine e.g. triethylamine, etc.
  • pyridine compound e.g. pyridine, lutidine, picoline, 4-dimethylaminopyridine, etc.
  • quinoline and the like.
  • the reaction is preferably carried out in the presence of a condensing agent such as a carbodiimide compound [e.g. N, N' -dicyclohexylcarbodiimide, N-cyclohexyl-N' - (4-diethylaminocyclohexyl) carbodiimide, N, N' -diethylcarbodiimide, N, ' -diisopropylcarbodiimide, N-ethyl-N'-( 3-dimethylaminopropyl) carbodiimide, etc . ] a ketenimine compound (e.g.
  • ethyl polyphosphate isopropyl polyphosphate, phosphoryl chloride, phosphorus trichloride, etc.
  • thionyl chloride oxalyl chloride, N-ethylbenzisoxazolium salt, N-ethyl-5-phenylisoxazolium-3-sulfonate, a reagent (referred to a so-called "Vilsmeier reagent") formed by the reaction of an amide compound such as N, -di (lower) alkylformamide (e.g. dimethylformamide, etc.), N-methylformamide or the like with a halogen compound such as thionyl chloride, phosphoryl chloride, phosgene or the like, and the like.
  • amide compound such as N, -di (lower) alkylformamide (e.g. dimethylformamide, etc.)
  • a halogen compound such as thionyl chloride, phosphoryl chlor
  • the reaction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, acetone, dichloromethane, alcohol (e.g. methanol, ethanol, etc.), tetrahydrofuran, pyridine, N, N-dimethylformamide, etc., or a mixture thereof.
  • a conventional solvent which does not adversely influence the reaction such as water, acetone, dichloromethane, alcohol (e.g. methanol, ethanol, etc.), tetrahydrofuran, pyridine, N, N-dimethylformamide, etc., or a mixture thereof.
  • the reaction temperature is not critical and the reaction is usually carried out under from cooling to heating .
  • the compound (I-r) or a salt thereof can be prepared by subjecting the compound (I-t) or a salt thereof to a removal reaction of the amino-protective group.
  • Suitable salts of the compound (I-t) may be the same as those for the compound (I) .
  • reaction of this process can be carried out in a manner similar to that in Process 1.
  • the compound (I-v) or a salt thereof can be prepared by subjecting the compound (I-u) or a salt thereof to a removal reaction of the hydroxy-protective group. Suitable salts of the compounds (I-u) and (I-v) may be the same as those for the compound (I) .
  • reaction of this process can be carried out in a manner similar to that in Process 1.
  • the compound (I-x) or a salt thereof can be prepared by oxidating the compound (I-w) or a salt thereof.
  • Suitable salts of the compounds (I-w) and (I-x) may be the same as those for the compound (I) .
  • reaction of this process can be carried out in a manner similar to that in Process 8.
  • Process 18 The compound (I-z) or a salt thereof can be prepared by reducing the compound (I-y) or a salt thereof.
  • Suitable salts of the compounds (I-y) and (I-z) may be the same as those for the compound (I) .
  • reaction of this process can be carried out in a manner similar to that in Process 3.
  • the compound (I-ab) or a salt thereof can be prepared by oxidating the compound (I-aa) or a salt thereof. Suitable salts of the compounds (I-aa) and (I-ab) may be the same as those for the compound (I) .
  • reaction of this process can be carried out in a manner similar to that in Process 2.
  • the compound (I-ac) or a salt thereof can be prepared by acylating the compound (I-v) or a salt thereof.
  • Suitable salts of the compound (I-ac) may be the same as those for the compound (I) .
  • the reaction of this process can be carried out in a manner similar to that in Process 14.
  • the compound (I-ad) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with the compound (XII) or a salt thereof.
  • Suitable salts of the compounds (I-ad), (XI) and (XII) may be the same as those for the compound (I) .
  • the reaction of this process can be carried out in a manner similar to that in Process 9.
  • the compound (I-p) or a salt thereof can be prepared by subjecting the compound (I-ae) or a salt thereof to a removal reaction of the carboxy-protective group.
  • Suitable salts of the compound (I-ae) may be the same as those for the compound (I) .
  • reaction of this process can be carried out in a manner similar to that in Process 1.
  • the compound (I-ag) or a salt thereof can be prepared by reacting the compound (I-af) or a salt thereof with a substituted amine.
  • Suitable salts of the compounds (I-af) and (I-ag) may be the same as those for the compound (I) .
  • reaction of this process can be carried out in a manner similar to that in Process 4.
  • the compounds obtained above can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation and the like.
  • the object compounds can be transformed into their salts in a conventional manner.
  • the object compounds may include one or more stereoisomers or optical isomers due to asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention.
  • Collagenases initiate the degradation of collagen in vertebrates and, in addition to their normal function in the metabolism of connective tissue and wound healing, they have been implicated to be involved in a number of pathological conditions such as joint destruction in rheumatoid arthritis, periodontal disease, corneal ulceration, tumor metastasis, osteoarthritis, decubitus restenosis after percutaneous transluminal coronary angiopsty, osteoporosis, psoriasis, chronic active hepatitis, autoimmune keratitis, and the like, and therefore the compounds of the present invention are useful for treating and/or preventing such pathological conditions .
  • Inhibitory activity of MMP can be assayed by a conventional test method as mentioned below.
  • Human collagenase was prepared from the culture medium of human skin fibroblast stimulated with interleukin-l ⁇ (1 ng/ml). Latent collagenase was activated by incubation with tryspin (200 ⁇ g/ml) at 37°C for 60 minutes and the reaction was stopped by adding soybean trypsin inhibitor (800 ⁇ g/ml). Collagenase activity was determined using FITC-labeled calf skin type I collagen.
  • FITC-collagen (2.5 mg/ml) was incubated at 37°C for 120 minutes with the activated collagenase and test compound in 50 mM Tris buffer (containing 5 mM CaCl 2 , 200 mM NaCl and 0.02% NaN 3 , pH 7.5). After stopping the enzyme reaction by adding the equal volume of 70% ethanol-200 mM Tris buffer (pH 9.5), the reaction mixture was centrifuged, and collagenase activity was estimated by measuring the fluorescence intensity of supernatant at 495 nm (excitation) and 520 nm (emission).
  • test compounds against human MMP-9 were measured by using commercial kits (Yagai, Japan). Gelatinolytic activity was determined by monitoring the degradation of FITC-labeled bovine type IV collagen after incubation for 4 hours at 42°C. The amount of degraded collagen was estimated by measuring the fluorescence intensity at 495 nm (excitation) and 520 nm (emission).
  • the inhibitory potential of test compounds against human MMP-13 were assayed by using commercial kit (Chondrex, USA) contained truncated form of human recombinant MMP-13 and fluorogenic peptide substrate.
  • Activity of human MMP-13 was determined by monitoring the degradation of fluorogenic peptide substrate after incubation for 1 hour at 35°C and estimated by measuring the fluorescence intensity of degraded peptide substrate at 495 nm (excitation) and 520 nm (emission) .
  • Inhibitory activity of human MMP-8 The inhibitory potential of test compounds against human MMP-8 were assayed by using commercial kit (Chondrex, USA) contained recombinant human pro-MMP-8 and FITC-labeled telopeptide-free soluble bovine type I collagen as a substrate. Recombinant human pro-MMP-8 was activated by a sequential incubation with mercury compound and proteinase at 35°C for 1 hour. Reaction mixture containing the activated MMP-8, substrate and test compounds were incubated at 35°C for 2 hours.
  • the reaction mixture was centrifuged and MMP-8 activity was estimated by measuring the fluorescence intensity of supernatant at 490 nm (excitation) and 520 nm (emission) .
  • the compounds and pharmaceutically acceptable salts thereof of the present invention can be used in the form of a pharmaceutical preparation containing, as an active ingredient, one of said compounds in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral or external administration.
  • a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral or external administration.
  • the pharmaceutical preparations may be capsules, tablets, dragees, granules, solutions, suspensions, emulsions, sublingual tablets, suppositories, ointments, and the like. If desired, there may be included, in these preparations, auxiliary substances, stabilizing agents, wetting agents, emulsifying agents, buffers and other commonly used additives.
  • a daily dose of 0.01 - 100 mg of the active ingredient per kg weight of a human being in the case of intravenous administration, a daily dose of 0.01 - 100 mg of the active ingredient per kg weight of a human being, and in the case of intramuscular administration, a daily dose of 0.05 - 100 mg of the same per kg weight of a human being, or in the case of oral administration, a daily dose of 0.1 - 100 mg of the same per kg weight of a human being, is generally given for the treatment of MMP or TNF ⁇ -mediated diseases .
  • Aib aminoisobutyric acid Abu: aminobutyric acid 4PyAla: 4-pyridylalanine
  • N-Chlorosuccinimide (2.67 g) was added gradually over 30 minutes to a stirred solution of tetrahydro-2H-thiopyran (2.04 g) in benzene (20 ml). The temperature was maintained at 20-30°C by intermittent external cooling. The mixture was stirred for 1 hour and rapidly filtered to remove succinimide. The filtrate was added to a solution of 4-anisylmagnesium bromide in diethyl ether which was prepared from 4-anisyl bromide (7.48 g) and magnesium turnings (0.875 g) in diethyl ether (36 ml) in a usual manner. The rate of addition was such that the temperature of the reaction was maintained between 10-15°C.
  • 5-Chlorovaleryl chloride (17.1 g) was added dropwise to a stirred suspension of aluminum chloride (14.7 g) in dichloromethane (125 ml) under a nitrogen atmosphere and ice cooling over 5 minutes and the resulting solution was stirred under the same conditions for 10 minutes, then therein a solution of 4-chlorodiphenyl ether (20.5 g) in dichloromethane (115 ml) was added dropwise over 20 minutes. The resulting mixture was stirred under the same conditions for 1 hour and 15 minutes, and poured into a mixture of 7% hydrochloric acid and ice. The organic layer was separated, washed with brine, dried over sodium sulfate, and evaporated in vacuo.
  • N-dimethylformamide 50 ml was added a solution of sodium carbonate (8.5 g) in degassed water (20 ml) and (2S) -N- [2- [2- (5-bromo-2-thienyl) -1, l-dioxo-3, 4, 5, 6- tetrahydro-2H-thio ⁇ yran-2-yl] acetyl] hydroxylamine trityl crowns (202 ⁇ mol, 10.1 ⁇ mol/crown x 20) in an atmosphere of nitrogen.
  • Example 1 1.5M Lithium diisopropylamide mono tetrahydrofuran in cyclohexane (0.28 ml) was added dropwise to a stirred suspension of 2- [4- ( 4-chlorophenoxy) phenyl] -3, , 5, 6- tetrahydro-2H-thiopyran 1,1-dioxide (117 mg) in tetrahydrofuran (2.4 ml) under dry ice - acetone cooling and a nitrogen atmosphere, and the mixture was stirred under the same conditions for 15 minutes, then a solution of tert-butyl bromoacetate (75 mg) in tetrahydrofuran (0.2 ml) was added dropwise therein and the resulting mixture was stirred under the same conditions for 2 hours.
  • Example 3 To a solution of ethyl 2- [5- ( 4-fluorophenyl ) -2- thienyl] -3, 4, 5, 6-tetrahydro-2H-thiopyran-2-acetate (315 mg) in methanol (4 ml) was added IN sodium hydroxide aqueous solution (1.3 ml) at 0°C and the mixture was stirred for 5 hours at room temperature. The resulting mixture was evaporated to remove methanol. The residue was acidified with IN hydrochloric acid (HCl) and extracted with ethyl acetate (x3) .
  • IN hydrochloric acid HCl
  • x3 ethyl acetate
  • Example 7 1.5M Solution of lithium diisopropylamide mono- tetrahydrofuran in cyclohexane (1.60 ml) was added dropwise to a stirred solution of 2- [ - (4-chlorophenoxy) phenyl] - 2, 3, 4 , 5-tetrahydrothiophene 1,1-dioxide (646 mg) in tetrahydrofuran (6.5 ml) under a nitrogen atmosphere and dry ice - acetone cooling, and the resultant solution was stirred under the same conditions for 35 minutes.
  • Example 22 2- [4- ( 4-Bromophenoxy) phenyl] -3,4,5, 6-tetrahydro-2H- thiopyran-2-acetic acid (3.99 g) was obtained in a similar manner to that of Example 21.
  • Example 23 Ethyl 2- [ 5- ( 4-fluorophenyl ) -2-thienyl ] -3 , 4 , 5 , 6- tetrahydro-2H-thiopyran-2-acetate (117 mg) was obtained from 7-amidinothio-3- [5- ( 4-fluorophenyl ) -2-thienyl] hept-2-enoate hydroiodide in a similar manner to that of Example 21.
  • Example 25 2- [4- (4-Fluorophenoxy) phenyl] -3,4,5, 6 ⁇ tetrahydro-2H- thiopyran-2-acetic acid (200 mg) was obtained in a similar manner to that of Example 24.
  • Example 26 2- [4- (4-Chlorophenyl)phenyl] -3, 4, 5, 6-tetrahydro-2H- thiopyran-2-acetic acid (310 mg) was obtained in a similar manner to that of Example 24.
  • Example 27 2- [4- ( 4-Bromophenyl) phenyl] -3,4,5, 6-tetrahydro-2H- thiopyran-2-acetic acid (120 mg) was obtained in a similar manner to that of Example 24.
  • Example 28 2- [4- (4-Fluorophenyl)phenyl] -3, 4, 5, 6-tetrahydro-2H- thiopyran-2-acetic acid (200 mg) was obtained in a similar manner to that of Example 24.
  • Example 31 l-Ethyl-3- (3-dimethylaminopropyl ) carbodiimide (WSCD) hydrochloride (205 mg) was added to a stirred mixture of 2- [4- (4-chlorophenoxy) phenyl] -3,4,5, 6-tetrahydro-2H-thiopyran- 2-acetic acid 1,1-dioxide (326 mg) , (R) -(+) - ⁇ -methylbenzylamine (105 mg) , and 1-hydroxybenzotriazole (123 mg) in dichloromethane (8 ml) under ice cooling, and then the resulting mixture was stirred at the same temperature for 2 hours and at room temperature for 2 hours and extracted with dichloromethane.
  • 2- [4- (4-chlorophenoxy) phenyl] -3,4,5, 6-tetrahydro-2H-thiopyran- 2-acetic acid 1,1-dioxide (326 mg)
  • Example 32 To a solution of (2R or 2S) -2- [4- ( 4-chlorophenoxy) - phenyl] -3, , 5, 6-tetrahydro-2H-thiopyran-2-acetic acid 1,1-dioxide (4.75 g) obtained in Example 10, 0-(2- tetrahydropyranyl ) hydroxylamine (2.11 g) , and

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Composé de formule (I) dans laquelle R1 représente alkyle inférieur, halogène, un groupe hétérocyclique éventuellement substitué ou aryle éventuellement substitué, R2 représente carboxy, carboxy protégé ou carboxy amidé, Ar représente aryle éventuellement substitué ou un groupe hétérocyclique éventuellement substitué, A représente alkylène inférieur, X représente oxa ou une liaison unique, Y représente thia, sulfinyle ou sulfonyle, Z représente méthylène, thia, sulfinyle ou sulfonyle, m et n sont chacun un nombre entier de 0 à 6, et 1≤m+n≤6, ou son sel, qui est utile en tant qu'inhibiteur de métalloprotéinases matricielles (MMP) ou du facteur de nécrose tumorale α (TNF α).
PCT/JP2000/000018 1999-01-07 2000-01-06 Compose cyclique Ceased WO2000040576A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MXPA01006896A MXPA01006896A (es) 1999-01-07 2000-01-06 Compuestos de tiopirano como inhibidores de metaloproteinas de matriz (mpm).
BR0008589-8A BR0008589A (pt) 1999-01-07 2000-01-06 Composto de tipirano, processo para sua preparação e seu uso
EP00900122A EP1140895B1 (fr) 1999-01-07 2000-01-06 Derives de thiopyrane comme inhibiteurs de mmp
KR1020017008512A KR20010102968A (ko) 1999-01-07 2000-01-06 시클릭 화합물
DE60009260T DE60009260T2 (de) 1999-01-07 2000-01-06 Thiopyranderivate as mmp-inhibitoren
CA002357874A CA2357874A1 (fr) 1999-01-07 2000-01-06 Compose cyclique
JP2000592284A JP2002534424A (ja) 1999-01-07 2000-01-06 Ｍｍｐ阻害剤としてのチオピラン化合物
AU18905/00A AU759900B2 (en) 1999-01-07 2000-01-06 Cyclic compound
HK02106999.6A HK1045312A1 (zh) 1999-01-07 2000-01-06 環狀化合物
AT00900122T ATE262517T1 (de) 1999-01-07 2000-01-06 Thiopyranderivate as mmp-inhibitoren

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPP8068 1999-01-07
AUPP8068A AUPP806899A0 (en) 1999-01-07 1999-01-07 Cyclic compound
AUPQ1702 1999-07-19
AUPQ1702A AUPQ170299A0 (en) 1999-07-19 1999-07-19 Cyclic compound

Publications (2)

Publication Number Publication Date
WO2000040576A2 true WO2000040576A2 (fr) 2000-07-13
WO2000040576A3 WO2000040576A3 (fr) 2001-03-22

Family

ID=25645967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/000018 Ceased WO2000040576A2 (fr) 1999-01-07 2000-01-06 Compose cyclique

Country Status (16)

Country Link
EP (1) EP1140895B1 (fr)
JP (1) JP2002534424A (fr)
KR (1) KR20010102968A (fr)
CN (1) CN1343206A (fr)
AR (1) AR022213A1 (fr)
AT (1) ATE262517T1 (fr)
BR (1) BR0008589A (fr)
CA (1) CA2357874A1 (fr)
DE (1) DE60009260T2 (fr)
ES (1) ES2213563T3 (fr)
HK (1) HK1045312A1 (fr)
HU (1) HUP0104859A3 (fr)
MX (1) MXPA01006896A (fr)
RU (1) RU2221792C2 (fr)
TR (1) TR200101936T2 (fr)
WO (1) WO2000040576A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
WO2003022842A1 (fr) * 2001-09-07 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. Bioxydes de thiophenylthiopyrane inhibiteurs du mmp- ou du tnf-alpha
WO2003031431A1 (fr) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Derives de sulfone cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
US6838466B2 (en) 2001-12-20 2005-01-04 Schering Corporation Compounds for the treatment of inflammatory disorders
WO2008134693A1 (fr) * 2007-04-30 2008-11-06 Abbott Laboratories Inhibiteurs d'enzyme diacylglycérol o-acyltransférase de type 1
WO2009096198A1 (fr) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations Nouveau derive de biaryle
WO2012017166A3 (fr) * 2010-07-19 2012-07-19 Vaxconsulting Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
WO2015028960A1 (fr) * 2013-08-28 2015-03-05 Piramal Enterprises Limited Dérivés hétérocycliques substitués en tant qu'agonistes de gpr et leurs utilisations

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
RU2536205C2 (ru) * 2012-09-27 2014-12-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Нефтехимии И Катализа Ран Способ получения 5-метоксикарбонил-1,3-дитиана, обладающего фунгицидной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801300D0 (en) * 1988-01-21 1988-02-17 May & Baker Ltd New compositions of matter
SU1643544A1 (ru) * 1989-02-07 1991-04-23 Институт Химии Нефти И Природных Солей Ан Казсср Алкиловые эфиры гетероциклических оксибутадииновых кислот в качестве мономеров дл получени полимеров, использующихс дл защиты от коррозии
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022842A1 (fr) * 2001-09-07 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. Bioxydes de thiophenylthiopyrane inhibiteurs du mmp- ou du tnf-alpha
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
US7015217B2 (en) 2001-10-09 2006-03-21 Bristol-Myers Squibb Company Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
WO2003031431A1 (fr) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Derives de sulfone cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
US7598242B2 (en) 2001-12-20 2009-10-06 Schering Corporation Compounds for the treatment of inflammatory disorders
US7034057B2 (en) 2001-12-20 2006-04-25 Schering Corporation Compounds for the treatment of inflammatory disorders
US6838466B2 (en) 2001-12-20 2005-01-04 Schering Corporation Compounds for the treatment of inflammatory disorders
WO2008134693A1 (fr) * 2007-04-30 2008-11-06 Abbott Laboratories Inhibiteurs d'enzyme diacylglycérol o-acyltransférase de type 1
EP2452937A1 (fr) * 2007-04-30 2012-05-16 Abbott Laboratories Inhibiteurs de l'enzyme diacylglycérol o-acyltransférase de type 1
US8242139B2 (en) 2007-04-30 2012-08-14 Abbott Laboratories Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
RU2497816C2 (ru) * 2007-04-30 2013-11-10 Эббви Инк. Ингибиторы фермента диацилглицерин о-ацилтрансферазы типа 1
US8901152B2 (en) 2007-04-30 2014-12-02 Abbvie Inc. Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
WO2009096198A1 (fr) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations Nouveau derive de biaryle
WO2012017166A3 (fr) * 2010-07-19 2012-07-19 Vaxconsulting Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US8975399B2 (en) 2010-07-19 2015-03-10 Jean-Francois Zagury Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF
WO2015028960A1 (fr) * 2013-08-28 2015-03-05 Piramal Enterprises Limited Dérivés hétérocycliques substitués en tant qu'agonistes de gpr et leurs utilisations

Also Published As

Publication number Publication date
CN1343206A (zh) 2002-04-03
HUP0104859A2 (en) 2002-10-28
EP1140895B1 (fr) 2004-03-24
BR0008589A (pt) 2002-01-29
JP2002534424A (ja) 2002-10-15
CA2357874A1 (fr) 2000-07-13
KR20010102968A (ko) 2001-11-17
DE60009260T2 (de) 2004-08-05
RU2221792C2 (ru) 2004-01-20
DE60009260D1 (de) 2004-04-29
HUP0104859A3 (en) 2002-11-28
MXPA01006896A (es) 2002-06-04
ATE262517T1 (de) 2004-04-15
HK1045312A1 (zh) 2002-11-22
EP1140895A2 (fr) 2001-10-10
AR022213A1 (es) 2002-09-04
WO2000040576A3 (fr) 2001-03-22
ES2213563T3 (es) 2004-09-01
TR200101936T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
US6489324B2 (en) Piperazine compounds as inhibitors of MMP or TNF
US6420427B1 (en) Aminobutyric acid derivatives
AU740263B2 (en) Thiol sulfonamide metalloprotease inhibitors
JP3034043B2 (ja) ピロリジンおよびチアゾリジン誘導体、それらの製造およびそれらを含んでいる薬剤
EP0677048B1 (fr) Inhibiteurs de proteases retrovirales contenant de la sulfone cyclique
CA2263932A1 (fr) Inhibiteurs 1,4-heterocycliques de metalloproteases
PT832061E (pt) Derivados de banzamida e sua utilizacao como antagonistas da vasopressina
EP0796270A2 (fr) Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no
EP1140895B1 (fr) Derives de thiopyrane comme inhibiteurs de mmp
MXPA04009374A (es) Derivados de tiazolidincarboxamida como moduladores del receptor de prostaglandina.
US6967197B2 (en) Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
WO2000063165A1 (fr) Inhibiteur mmp
AU759900B2 (en) Cyclic compound
US6207686B1 (en) Endothelin antagonists
JP3470692B2 (ja) アミノブタン酸誘導体
WO2003018019A2 (fr) Nouvelle utilisation de compose cyclique
AU2001234097A1 (en) Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
AU5412298A (en) Piperazine compounds as inhibitors of mmp or tnf
MXPA99005822A (en) Piperazine compounds as inhibitors of mmp or tnf
JP2003212831A (ja) アミノブタン酸誘導体

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00804771.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 18905/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000900122

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020017008512

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2357874

Country of ref document: CA

Ref document number: 2357874

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006896

Country of ref document: MX

Ref document number: 2001/01936

Country of ref document: TR

Ref document number: 09868894

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1016/CHE

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2000900122

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017008512

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 18905/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000900122

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017008512

Country of ref document: KR